Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971083 | 1.00 | CTSK (0.42) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4096308 | 1.00 | CTSK (0.42) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL18248134 | 0.88 | CTSK (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1162846 | 0.86 | TGFBR1 (0.41) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL12805714 | 0.86 | TGFBR1 (0.41) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL8751934 | 0.84 | CYP2D6 (0.36) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL21877891 | 0.84 | GRN (0.38) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL21877890 | 0.84 | GRN (0.38) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL2586168 | 0.84 | MEN1 (0.36) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1162906 | 0.84 | MEN1 (0.36) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897972-B1 | 2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2016-11-30 | — | — | EP | disclosed |
| EP-2897972-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014044622-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-27 | — | — | WO | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| EP-2253614-B1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-1735307-B1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281845-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| CN-1964970-A | Inhibitors of IAP | NOVARTIS AG (CH) | 2007-05-16 | — | — | CN | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | CTSK 3081/4885CTSS 3187/4885MEN1 2628/4885 |
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | CTSK 2123/4885CTSS 1906/4885MEN1 2598/4885 |
| US-20110281845-A1 | ORGANIC COMPOUNDS | XIAP, BAX, MCL1 | CTSK 3080/4885CTSS 3185/4885MEN1 2630/4885 |
| US-20110281875-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | CTSK 2630/4885CTSS 2388/4885MEN1 2365/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | CTSK 3637/4885CTSS 3056/4885MEN1 3135/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | CTSK 2630/4885CTSS 2388/4885MEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.